Drug Type miRNA, CRISPR/Cas, AAV based gene therapy |
Synonyms AAV HTTamiRNA, AAVHTTamiRNA |
Target |
Action inhibitors, modulators |
Mechanism Huntingtin inhibitors, SOD1 modulators(Superoxide dismutase modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Amyotrophic Lateral Sclerosis | Preclinical | United States | 13 May 2025 | |
| Huntington Disease | Preclinical | United Kingdom | 08 May 2024 |





